Advertisement

Epidemiology and Pathophysiology

  • Bum Sik Tae
  • Chang Wook Jeong
Chapter

Abstract

Upper urinary tract urothelial carcinoma (UTUC) can be defined as any neoplastic growth that affects the lining of the urinary tract from the renal calyces to the distal ureter. UTUC has similar behaviors to urothelial cell carcinoma in bladder (UBC), but prognosis and tumor characteristics are different. However, UTUC is known as a relatively rare disease and has poor prognosis than UBC.

Keywords

Upper tract urothelial carcinoma Epidemiology Stage Pathology 

References

  1. 1.
    Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111.CrossRefGoogle Scholar
  2. 2.
    Audenet F, Colin P, Yates DR, Ouzzane A, Pignot G, Long JA, et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. BJU Int. 2012;110:E583–9.CrossRefGoogle Scholar
  3. 3.
    Chen XP, Xiong GY, Li XS, Matin SF, Garcia M, Fang D, et al. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int. 2013;112:917–24.PubMedGoogle Scholar
  4. 4.
    Grasso M, Fishman AI, Cohen J, Alexander B. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int. 2012;110:1618–26.CrossRefGoogle Scholar
  5. 5.
    Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52:594–601.CrossRefGoogle Scholar
  6. 6.
    Holmang S, Johansson SL. Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol. 2006;175:69–72; discussion-3.CrossRefGoogle Scholar
  7. 7.
    Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G, et al. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol. 2009;182:2177–81.CrossRefGoogle Scholar
  8. 8.
    Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009;45:3291–7.CrossRefGoogle Scholar
  9. 9.
    Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A. 2012;109:8241–6.CrossRefGoogle Scholar
  10. 10.
    Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer. 1999;85:1342–4.CrossRefGoogle Scholar
  11. 11.
    Yang MH, Chen KK, Yen CC, Wang WS, Chang YH, Huang WJ, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology. 2002;59:681–7.CrossRefGoogle Scholar
  12. 12.
    Fang D, Xiong G, Li X, Kang Y, Zhang L, Zhao G, et al. Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population. Urol Oncol. 2015;33:66.e1–11.CrossRefGoogle Scholar
  13. 13.
    Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164:1523–5.CrossRefGoogle Scholar
  14. 14.
    Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Association between demographic factors and prognosis in urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis. Oncotarget. 2017;8:7464–76.PubMedGoogle Scholar
  15. 15.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33.CrossRefGoogle Scholar
  16. 16.
    Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012;61:1069–70.CrossRefGoogle Scholar
  17. 17.
    Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 2009;104:1436–40.CrossRefGoogle Scholar
  18. 18.
    Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985;313:292–5.CrossRefGoogle Scholar
  19. 19.
    McCredie M, Stewart JH, Ford JM, MacLennan RA. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol. 1983;55:220–4.CrossRefGoogle Scholar
  20. 20.
    Steffens J, Nagel R. Tumours of the renal pelvis and ureter. Observations in 170 patients. Br J Urol. 1988;61:277–83.CrossRefGoogle Scholar
  21. 21.
    Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh urology: expert consult premium edition: enhanced online features and print, 4-volume set. Philadelphia: Elsevier Health Sciences; 2011.Google Scholar
  22. 22.
    Stewart JH, Hobbs JB, McCredie MR. Morphologic evidence that analgesic-induced kidney pathology contributes to the progression of tumors of the renal pelvis. Cancer. 1999;86:1576–82.CrossRefGoogle Scholar
  23. 23.
    Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007;104:12129–34.CrossRefGoogle Scholar
  24. 24.
    Ross RK, Paganini-Hill A, Landolph J, Gerkins V, Henderson BE. Analgesics, cigarette smoking, and other risk factors for cancer of the renal pelvis and ureter. Cancer Res. 1989;49:1045–8.PubMedGoogle Scholar
  25. 25.
    Brenner DW, Schellhammer PF. Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review. J Urol. 1987;137:1226–7.CrossRefGoogle Scholar
  26. 26.
    Kim HS, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Histological variant as the significant predictor of survival in patients with lymph node positive urothelial carcinoma of the bladder. Sci Rep. 2015;5:9626.CrossRefGoogle Scholar
  27. 27.
    Shibing Y, Turun S, Qiang W, Junhao L, Haichao Y, Shengqiang Q, et al. Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy. Urol Oncol. 2015;33:204.e9–16.CrossRefGoogle Scholar
  28. 28.
    Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, et al. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol. 2012;188:398–404.CrossRefGoogle Scholar
  29. 29.
    Tang Q, Xiong G, Li X, Fang D, Xi C, Zhang L, et al. The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World J Urol. 2016;34:871–7.CrossRefGoogle Scholar
  30. 30.
    Kim JK, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urol Oncol. 2017;35:458.e9–458.e15.CrossRefGoogle Scholar
  31. 31.
    Perez-Montiel D, Hes O, Michal M, Suster S. Micropapillary urothelial carcinoma of the upper urinary tract: clinicopathologic study of five cases. Am J Clin Pathol. 2006;126:86–92.CrossRefGoogle Scholar
  32. 32.
    Modi H, Beckley I, Bhattarai S, Spencer J, Cartledge J. Lymphoepithelioma-like carcinoma of the renal pelvis: pathological and therapeutic implications. Can Urol Assoc J. 2013;7:E590.CrossRefGoogle Scholar
  33. 33.
    Perez-Montiel D, Wakely PE, Hes O, Michal M, Suster S. High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Pathol. 2006;19:494–503.CrossRefGoogle Scholar
  34. 34.
    Suster S, Robinson MJ. Spindle cell carcinoma of the renal pelvis. Immunohistochemical and ultrastructural study of a case demonstrating coexpression of keratin and vimentin intermediate filaments. Arch Pathol Lab Med. 1989;113:404–8.PubMedGoogle Scholar
  35. 35.
    Perez-Montiel D, Suster S. Upper urinary tract carcinomas: histological types and unusual morphological variants. Diagn Histopathol. 2008;14:48–54.CrossRefGoogle Scholar
  36. 36.
    Li MK, Cheung WL. Squamous cell carcinoma of the renal pelvis. J Urol. 1987;138:269–71.CrossRefGoogle Scholar
  37. 37.
    Blacher EJ, Johnson DE, Abdul-Karim FW, Ayala AG. Squamous cell carcinoma of renal pelvis. Urology. 1985;25:124–6.CrossRefGoogle Scholar
  38. 38.
    Sheaff M, Fociani P, Badenoch D, Baithun S. Verrucous carcinoma of the renal pelvis: case presentation and review of the literature. Virchows Arch. 1996;428:375–9.CrossRefGoogle Scholar
  39. 39.
    Oliva E, Amin MB, Jimenez R, Young RH. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems. Am J Surg Pathol. 2002;26:190–7.CrossRefGoogle Scholar
  40. 40.
    Sahin AA, Myhre M, Ro JY, Sneige N, Dekmezian RH, Ayala AG. Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma. Acta Cytol. 1991;35:277–80.PubMedGoogle Scholar
  41. 41.
    Guillou L, Duvoisin B, Chobaz C, Chapuis G, Costa J. Combined small-cell and transitional cell carcinoma of the renal pelvis. A light microscopic, immunohistochemical, and ultrastructural study of a case with literature review. Arch Pathol Lab Med. 1993;117:239–43.PubMedGoogle Scholar
  42. 42.
    Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, et al. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology. 2006;67:518–23.CrossRefGoogle Scholar
  43. 43.
    Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73:560–9.CrossRefGoogle Scholar
  44. 44.
    Gospodarowicz MK, Brierley JD, Wittekind C. TNM classification of malignant tumours. Chichester: Wiley; 2017.Google Scholar
  45. 45.
    Soukup V, Capoun O, Cohen D, Hernandez V, Babjuk M, Burger M, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur Urol. 2017;72:801–13.CrossRefGoogle Scholar
  46. 46.
    Solsona E, Iborra I, Ricos JV, Dumont R, Casanova JL, Calabuig C. Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management. Urology. 1997;49:347–52.CrossRefGoogle Scholar
  47. 47.
    Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE. Upper urinary tract recurrence after radical cystectomy for bladder cancer—who is at risk? J Urol. 2009;182:2632–7.CrossRefGoogle Scholar
  48. 48.
    Wright JL, Hotaling J, Porter MP. Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis. J Urol. 2009;181:1035–9; discussion 9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Korea University College of MedicineSeoulSouth Korea
  2. 2.Department of UrologyKorea University Ansan HospitalAnsanSouth Korea
  3. 3.Department of UrologySeoul National University HospitalSeoulSouth Korea

Personalised recommendations